A company that produces nine-valent vaccines.

Nine-valent vaccine concept stocks in 2022 for your reference.

1, Renhe Pharmaceutical: the operating income in 2020 is 41060,000, up-10.37% year-on-year.

The company invested in Jiangsu Ruike Biotechnology Co., Ltd. through Nanjing Zhao Yin Modern Industry No.2 Equity Investment Fund (Limited Partnership). The core team of the company has more than 20 years of experience in research, development and industrialization of biological products, and has obtained the clinical research approval documents of bivalent vaccine of HPV1618, bivalent vaccine of HP V6/1KLOC-0/bivalent vaccine of human papillomavirus with independent intellectual property rights. The product quality and output have reached the international advanced level, and the follow-up pre-clinical research on recombinant human growth hormone and genetically engineered herpes zoster vaccine is under way. In the third quarterly report of 20021,the company's revenue was 3.659 billion yuan and its net profit was 5247 1.74 million yuan, up 38.29% year-on-year.

In the past seven trading days, Renhe Pharmaceutical Co., Ltd. has fallen by 12. 12%, the highest price is 7.7 yuan, and the total market value has fallen by165438+76 million yuan, down by 12.438+02%.

2. watson biological: 202 1, the company's operating income was 3.463 billion, up 17.82% year-on-year.

Yunnan watson biological Technology Co., Ltd. is a biopharmaceutical company specializing in the research, development, production and sales of human vaccine products, and is committed to providing safe and effective, high-quality and technologically advanced human vaccine products to domestic and foreign markets.

In the last seven days, watson biological's share price fell by 17.59%, and in 2022 it fell by-12. 16%, with the highest price of 6 1. 15 yuan, with a market value of 78.653 billion yuan.

3. zhifei Biology: The annual report of 2020 shows that the company's operating income is1510.9 billion yuan, up 43.48% year-on-year, with a compound growth rate of 43.48% in recent three years.

At present, the products on sale include independent products such as AC group meningococcal combined vaccine of Haemophilus influenzae B, Haemophilus influenzae B, A, C, Y, W 135 group meningococcal polysaccharide vaccine, Mycobacterium bovis for injection, A group C group meningococcal polysaccharide vaccine and so on, as well as the unified sale of 23-valent pneumococcal polysaccharide vaccine, inactivated hepatitis A vaccine, tetravalent human papillomavirus vaccine and nine-valent human vaccine authorized by Merck.

Looking back on the past seven trading days, zhifei Bio has fallen for four days. During the period, the overall decline was 17.6%, the highest price was 133 yuan, the lowest price was 1.465438 0.2 yuan, and the total turnover was1.800 million lots.

All the information in Southern Fortune Network does not constitute investment advice, and the stock market is risky, so investment needs to be cautious.